Pfizer Biotech Sweden offers contract manufacturing
Pfizer’s biotech facility in Sweden has a long tradition of microbial bioprocessing with a heritage from the Swedish company Pharmacia that started the production already in 1955. Today, Pfizer’s biotech production process is a modern and highly automated biotechnical facility based on a new innovative technology platform. The new platform provides flexibility to produce several different products in the same plant. Pfizer has invested SEK 1.5 billion in this new state-of-the-art multi product facility, in Sweden which was inaugurated in 2009.
In 2011 the plant was awarded the “Facility of the Year Award” In the category of Operational Excellence by the International Society for Pharmaceutical Engineering.
Today the facility is producing biopharmaceutical substances for preventing blood clots and growth hormone disorders. Historically, the focus areas have been bacterial expression systems with a variety of large molecules.
Through our value proposition initiative and innovative process improvements in collaboration with Pfizer’s global functions, the production capacity has doubled and the facility is ready to offer the capacity to produce new biotech products and services to external partners.
The external partners using Pfizer Biotech Sweden as their CMO supplier benefit from the small plant's cost-effective, agile and flexible manufacturing capability as well as the large global company’s knowledge of technology transfer and cGMP pharmaceutical manufacturing. Pfizer Biotech Sweden has the capability to support all the way from development, clinical material to an approved commercial product according to known global regulatory requirements.
By chosing Pfizer Biotech Sweden, you would be partnering with a company that truly understands the numerous challenges and requirements of the pharmaceutical industry provided by a global Pfizer organization, Pfizer Centre Source.